Weekly High-dose 5-Fluorouracil (5-FU), Leucovorin (LV) and Bimonthly Cisplatin in Patients with Advanced Gastric Cancer
|
|
- Reynard Norman
- 6 years ago
- Views:
Transcription
1 Jpn J Clin Oncol 2001;31(12) Weekly High-dose 5-Fluorouracil (5-FU), Leucovorin (LV) and Bimonthly Cisplatin in Patients with Advanced Gastric Cancer Yung-Chang Lin 1,Jen-ShiChen 1, Cheng-Hsu Wang 1, Hung-Ming Wang 1, Hseng-Kun Chang 1, Chi-Ting Liau 1, Tsai-Shen Yang 1, Chuang-Chi Liaw 1 and Hsueh-Erh Liu 2 1 Division of Hematology Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taipei and 2 School of Nursing, Chang Gung University, Taipei, Taiwan Received May 18, 2001; accepted August 27, 2001 Background: A phase II clinical trial was performed to evaluate the activity and toxicity of bimonthly cisplatin and weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced gastric cancer. Patients and methods: From September 1997 to March 1998, 23 chemo-naive patients of advanced gastric cancer were enrolled in this study. The regimen consisted of weekly 24-h infusion of 5-FU (2600 mg/m 2 ) and LV 150 mg and bimonthly cisplatin (25 50 mg/m 2 ) bolus for 12 weeks followed by a 2-week break. Results: There were 10 male and 13 female patients with a median age of 52 years. A total of 428 chemotherapy treatments were given with a mean of 11. Seventeen patients were evaluable for response. There were 41% (7/17) partial response, 18% (3/17) stable disease and 41% (7/17) progressive disease. The grade III or IV toxicity included anorexia 35% (8/23), fatigue 26% (6/23), vomiting 17% (4/23) and mucositis 9% (2/23). One patient developed perforated duodenal stump after chemotherapy. One patient died of hyperammonemia-related coma. The median times to disease progression and overall survival were 3.5 and 7 months, respectively. Conclusions: This regimen showed modest activity against gastric cancer. However, there was no survival advantage and there was greater toxicity than with weekly high-dose 5-FU LV alone. Key words: chemotherapy stomach neoplasms fluorouracil cisplatin INTRODUCTION Gastric cancer is the second leading cancer worldwide, with a current 5-year survival rate of <20% (1,2). About 25% of patients with gastric cancer are associated with disseminated disease at presentation and more than half of patients with localized disease recur within 5 years (1 6). Advanced disease is incurable and patients will be treated by chemotherapy if their condition allows. A number of effective chemotherapy combination regimens have been developed in advanced and metastatic gastric cancer, but there is no worldwide consensus For reprints and all correspondence: Yung-Chang Lin, Division of Hematology Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, 199 Tung-Hwa North Road, Taipei, Taiwan. yclinof@adm.cgmh.org.tw Abbreviations: 5-FU, 5-fluorouracil; LV, leucovorin; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; WHO, World Health Organization regarding a standard regimen. 5-Fluorouracil (5-FU)-based regimens, used either alone or in combination with other drugs, are commonly used in general clinical practice, but the response rate is only 20 50% with very few complete responses (6 11). To date, most of the chemotherapy to patients with metastatic gastric cancer has been for palliation only. Our previous studies using weekly high-dose 24-h infusion of 5-FU and leucovorin (LV) to chemotherapy-naive patients with gastric cancer revealed a partial response rate of 33% (95% confidence interval: 18 50%) and a median survival of 7 months (12). This regimen was considered to be effective and with acceptable toxic profiles for patients with gastric cancer, even in patients with poor performance status. However, there were no complete responses and the responses were not durable. We therefore suggest that this regimen should be modified as a basis for combination trials to improve the response rate and survival duration by overcoming the drug resistance of 5-FU. Cisplatin is probably the second most common agent employed for gastric cancer in Europe, much more common 2001 Foundation for Promotion of Cancer Research
2 606 5-FU, LV and CDDP in gastric cancer than anthracyclines. The combination of 5-FU and cisplatin in patients with gastric cancer has been tested (13 15). Cisplatin was found to have a synergistic effect when combined with 5- FU in experimental models. Administration of cisplatin inhibited intracellular L-methionine metabolism, thus resulting in a several-fold increase in reduced folate and enhanced the 5-FU cytotoxicity (16). The 5-FU and cisplatin combination is considered to be one of the standards or reference regimens for gastric cancer in many centers. There have been three phase II studies in Europe, using infusional 5-FU with cisplatin; the response rates ranged from 41 to 48% and median overall survivals were 9 10 months (13 15). In addition, a randomized phase III study in Korea showed that the 5-FU and cisplatin combination was better than 5-FU, adriamycin, mitomycin C (FAM) or 5-FU alone in terms of response rate and time to progression (17). We therefore suggest that cisplatin is a reasonable agent to combine with the weekly high-dose 5-FU LV regimen to yield a higher response rate and longer duration than with 5-FU LV alone. The original 5-FU cisplatin combination usually gives cisplatin at a dose of 100 mg/m 2 every 3 4 weeks. Because we intended to use this regimen on an outpatient basis, we split the dose of cisplatin to 50 mg/m 2 twice a month. Actually, the dose intensity is equal to the common 5- FU cisplatin combination. Consequently, we designed this phase II prospective clinical trial by using weekly high-dose 5- FU LV and bimonthly cisplatin combination in patients with gastric cancer. PATIENTS AND METHODS All patients were required to have a known primary gastric cancer beyond hope of cure, that is, histological proof of residual primary, recurrent or metastatic disease. The tumors were required to be radiologically measurable or evaluable. Patients should have no prior chemotherapy, a Karnofsky performance status 30, absolute granulocyte count 1500/l, platelet count /l, serum creatinine concentration 2 mg/dl and serum bilirubin 3.0 mg/dl. Written informed consent was obtained prior to therapy. All patients received a central vascular device through subclavian vein for outpatient infusion therapy. The chemotherapy consisted of 5-FU 2600 mg/m 2 with LV 150 mg, which was infused simultaneously through a portable pump for 24 h. It was preceded by a bolus infusion of cisplatin mg/m 2 in 0.9% saline, 500 ml for 3 h every other week. The first eight patients were treated with cisplatin at a dose of 50 mg/m 2. However, because unacceptable toxicity occurred in all of these patients, the dosage of cisplatin was reduced to 25 mg/m 2 on subsequent patients. Standard pre-medication with antiemetics such as steroids and serotonin antagonist was given. Patients were planned to have chemotherapy every week for 12 weeks, then a 2-week rest. If a grade III hematological or gastrointestinal toxicity (according to the WHO Toxicity Guidelines) was observed, the dose of cisplatin was reduced to 25 mg/m 2. The course of chemotherapy was repeated every 14 weeks until disease progression, unacceptable toxicity or patient refusal. Prior to the therapy, all patients were evaluated by a complete history review, physical examination, complete blood counts, biochemistry profile, serum tumor marker, chest roentgenogram and abdominal computed tomography (CT) scan. Patients were re-assessed after 12 weeks by the same procedures. In instances of clinical suspicion of progressive disease (PD) during treatment, the evaluation was performed immediately. Complete response (CR) was defined as the disappearance of all measurable disease based on the image studies. Partial response (PR) was defined as a 50% decrease in the sum of the products of the largest perpendicular diameters of all the measurable lesions or a decrease of at least 50% of the one dimension of the evaluable lesions for at least 4 weeks without the appearance of the new lesions. Stable disease (SD) was defined as a decrease of the lesions for at least 4 weeks, which did not reach the criteria of PR or a <25% increase of lesions. PD was defined as a 25% increase in the size of one or more evaluable lesions or the appearance of new lesions. The presence of ascites was not considered to be a criterion of measuring response; however, a new appearance of ascites was considered to be a progression. The estimated sample size was 29 patients under an expected response rate of 30% using Simon s two-stage design. However, because of the toxicity, this study was terminated early after internal review. The time to progression was measured from the start of the therapy to the date of progression. One patient who died without observing evidence of disease progression was treated as an event at the time of death. Otherwise, such a patient was censored at the time of latest examination certifying no evidence of progression. The survival time was calculated from the start of the therapy to the date of death and survival time was established by the Kaplan Meier method. RESULTS From September 1997 to March 1998, 23 consecutive patients were registered in this study. The patients characteristics are summarized in Table 1. There were 10 males and 13 females with a median age of 52 years (range, years). The mean Karnofsky performance status was 65.7% (range, 50 80%). The sites of diseases included stomach (14), peritoneum (11), intra-abdominal lymph nodes (6), liver (3), bone (1) and ovary (1). A total of 428 chemotherapy treatments were given (range, 1 19) with a mean of 11. Dose reduction of cisplatin or termination of the studies due to unacceptable toxicity was required for the first eight patients using cisplatin at 50 mg/m 2.The toxicities included WHO grade III or IV thrombocytopenia (one patient), nausea or vomiting (three patients), mucositis (one patient), hand foot syndrome (one patient), consciousness change (two patients) and grade II or III fatigue (five patients). Among them, one patient died of consciousness disturbance from hyperammonemia. Therefore, we decided to reduce the
3 Jpn J Clin Oncol 2001;31(12) 607 Table 1. Patients characteristics (n = 23) Gender Male 10 Female 13 Median age (years) 52 (range 24 70) Performance status (Karnofsky) 65.7 (mean, range 50 80) 80 90% % % 4 Tumor site Loco-regional 14 Peritoneum 11 Lymph nodes 6 Liver 3 Bone 1 Ovary 1 doseofcisplatinto25mg/m 2 for the following 15 patients. After dose reduction, none of the patients left the study due to toxicity, only one patient had grade III vomiting and one had grade III mucositis. Only 17 patients were eligible for analyzing response. The overall response rate was 41% (7/17) (95% confidence interval: 17 67%) without any complete response; 18% of the patients showed stable disease and 41% developed progressive disease. All of the responders were in the group of patients receiving 25 mg/m 2 cisplatin. The response rate in this subset, therefore, was 47%. However, the study s intend-to-treat response rate was 30%. The median follow-up period was 7 months. The overall median time to disease progression was 3.5 months. The overall median survival was 7 months (Fig. 1). Figure 1. Survival curve estimated by the Kaplan Meier method. Table 2. Maximum toxicity grade (WHO) (n =23) Grade Leukocytes 19 (83%) 1 (4%) 3 (13%) 0 0 Platelets 20 (87%) 1 (4%) 2 (9%) 0 0 Mucositis 12(52%) 5(22%) 4(17%) 2(9%) 0 Nausea/vomiting 8 (35%) 6 (26%) 5 (22%) 3 (13%) 1 (4%) Fatigue 5 (22%) 5 (22%) 7 (30%) 6 (26%) Diarrhea 20 (87%) 3 (13%) Neurotoxicity* 21 (91%) (9%) Hand foot syndrome 19 (83%) 0 3 (13%) 1 (4%) *Hyperammonemia-associated toxicity. The toxicity profiles are summarized in Table 2. Grade III or IV toxicity included fatigue 26% (6/23), vomiting 17% (4/23) and mucositis 9% (2/23). In addition, one patient had a perforated duodenal stump immediately after the first dose of chemotherapy. Two patients showed hyperammonemia-associated consciousness changes. One patient developed visual hallucination and incoherent speech during infusion, but recovered spontaneously after chemotherapy. The other patient showed consciousness disturbance, fever and hypotension with an elevation of serum ammonia level during chemotherapy, and died later due to uncontrolled shock. His case was considered to be treatment-related death. A patient complained of acute upper abdominal pain with a standing chest film of subphrenic free air 4 days after the first dose of chemotherapy. An emergency laparotomy was performed which revealed a perforated peptic ulcer at the duodenum. He survived after surgery but was removed from the study later. DISCUSSION The present study revealed a 41% response rate but a significant toxicity compared with the previous 5-FU LV trial, while the survival was the same (12). Most of the grade III or IV side effects occurred in the first eight patients who received bimonthly 50 mg/m 2 cisplatin prior to 5-FU LV infusion. Among these patients, fatigue was the most common toxicity, followed by nausea and vomiting. The most disturbing adverse effect, fatigue, led to the reduction of cisplatin to 25 mg/m 2 on the subsequent 15 patients. After the reduction, the toxicity was manageable and the patient compliance improved. In addition, four patients survived longer than 18 months, which was not frequently seen in patients received 5-FU LV alone (12). The durable responses were attributed to the inhibition of resistant clones by combination chemotherapy. In comparison with those of the 5-day infusion of 5-FU and cisplatin combination, the response rate and the survival of the present study did not differ, but the toxic profile was better (13 15). Chi et al. (18) used weekly 24-h infusion of high-dose 5-FU LV with cisplatin, epidoxorubicin and etoposide and
4 608 5-FU, LV and CDDP in gastric cancer reported <10% grade III or IV toxicity. The favorable toxicity profile may attributed to the different cisplatin infusion schedule and low-dose chemotherapy (18). Kretzschmar et al. (19) applied a weekly 24-h infusion of high-dose 5-FU plus LV in combination with mitomycin C; a response rate of 37% was reported without complete response. There were 23% grade III neutropenia and 13% grade III thrombocytopenia. However, the median time to disease progression and overall survival were only 5 and 7 months, respectively. In addition, Bokemeyer et al. (20) reported a combination of weekly high-dose 5-FU LV and paclitaxel. Among the 26 patients with gastric cancer, the response rate was 32% without complete response. However, the progression-free survival and median overall survival were up to 8 and 11 months, respectively. There were 14% grade III/IV neutropenia and 45% alopecia from the toxicity of paclitaxel. The combination was suggested to be comparable to ELF or FAMTX and the toxicity allowed administration on an outpatient basis (20). However, there was no randomized comparison to confirm the superiority of weekly high-dose 5-FU LV combination over others. There is an ongoing randomized trial of a weekly high-dose 5-FU LVbased regimen, which may answer this question (21). The unusual complication of fatigue was not seen with the 5- FU cisplatin combination when the 5-FU was given as a 5-day continuous infusion and 100 mg/m 2 cisplatin as a 3-h infusion in patients within the same ethnic population (22), but was seen in patients with weekly high dose 5-FU LV alone, where 90% of patients experienced a mild degree of fatigue (12). However, the severity of fatigue was much higher in the present trial where 26% of the patients experienced WHO grade II or III fatigue and five patients dropped out owing to fatigue. The increased frequency and severity of fatigue may be related to the addition of cisplatin to the 5-FU LV-based regimen. However, a weekly high-dose 5-FU LV and cisplatin combination has been reported in patients with gastric cancer and nasopharyngeal carcinoma in the same patient ethnic group, but the cisplatin was administered as a 24-h continuous infusion (18,23). The authors did not report the toxicity of fatigue and claimed that the overall toxicity was minimal. Whether the change of cisplatin infusion schedule results in decreased fatigue in patients with gastric cancer remains elusive. 5-FU chemotherapy-related hyperammonemia was a complication from high-dose 5-FU infusion therapy. It has been reported in the literature, but its mechanism remains unclear (24). In our previous study, three patients had similar hyperammonemia-associated consciousness changes; two recovered spontaneously after discontinuation of the therapy and the third died owing to profound consciousness changes. The present study did not show an increase in the frequency of hyperammonemia compared with the previous 5-FU LV alone therapy. Weekly high-dose 5-FU LV has a modest response for patients with gastric cancer and with acceptable toxicity. This promising regimen has been increasingly used as a base of combination chemotherapy for gastric cancer, although it has not been proved by randomized trials. We added cisplatin to this regimen and obtained an equal response rate but increased toxicity compared with 5-FU LV alone. We conclude that there was no advantage in combining mg/m 2 of bimonthly cisplatin with high dose 5-FU LV. We should look for other active agents to combine with the 5-FU LV-based regimen such as taxnes, CPT-11 and oxaliplatin. Acknowledgment This research was supported in part by the National Science Council, Republic of China, grant NSC B References 1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer Statistics, CA Cancer J Clin 1997;47: Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. Semin Oncol 1996;3: Bruckner HW, Stablein DM. Sites of treatment failure: gastrointestinal tumor study group analyses of gastric, pancreatic and colorectal cancer. Treat Symp 1983;2: Kennedy BJ. TNM classification of stomach cancer. Cancer 1970;26: Kinoshita T, Maruyama K, Sasako M, Okajima K. Treatment results of gastric cancer patients: Japanese experience. In: Nishi M, Ichikawa H, Nakajima T, Tahara E, editors. Gastric Cancer. Berlin: Springer 1993; Wils J. The treatment of advanced gastric cancer. Semin Oncol 1996;23: Wils J, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin a step ahead in the treatment of advanced gastric cancer, a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. JClinOncol1991;9: Findlay M, Cunningham D. Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 1993;19: MacDonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, et al. 5-Fluorouracil, doxorubicin and mitomycin-c (FAM) combination chemotherapy for advanced gastric cancer. AnnInternMed1980;93: Preusser P, Achterrath W, Wilke H, Lenaz L, Fink U, Heinicke A, et al. Chemotherapy of gastric cancer. Cancer Treat Rev 1988;15: Wilke H, Preusser P, Fink U, Achterrath W, Lenaz L, Stahl M, et al. Highdose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 1990;8: Chen JS, Liu HE, Wang CH, Yang TS, Wang HM, Liau CT, et al. Weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced gastric cancer. Anticancer Drugs 1999;10: Lacave AJ, Baron FJ, Anton LM, Estrada E, De Sande LM, Palacio I, et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 1991;2: Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinoma. A phase II trial with prognostic factor analysis. Eur J Cancer 1994;30A: WilkeH,PreusserP,FinkW,AchterrathW,MeyerHJ,StahlM,etal. New developments in the treatment of gastric carcinoma. Semin Oncol 1990;17(Suppl 2): Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993;32: Kim NK, Park YS, Hoe DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:
5 Jpn J Clin Oncol 2001;31(12) Chi KH, Chao Y, Chan WK, Lo SS, Chen SY, Yen SH, et al. Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer. Br J Cancer 1998;77: Kretzschmar A, Reichardt P, Thuss-Patience PC, Hohenberger P, Benter T, Dorken B, et al. Weekly 24-h infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer. Oncology 2000;59: Bokemeyer C, Lampe CS, Clemens MR, Hartmann JT, Quietzsch D, Forkmann L, et al. A phase II trial of paclitaxel and weekly 24 hours infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs 1997;8: Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Custem E, et al. Final results of a randomized phase III trial of sequential highdose methotrexate, fluorouracil and doxorubicin versus etoposide, leucovorin and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. JClinOncol2000;18: Wang HM, Wang CH, Chen JS, Lo SS, Chen SY, Yen SH, et al. Cisplatin and 5-fluorouracil as neoadjuvant chemotherapy: predicting response in head and neck squamous cell cancer. J Formos Med Assoc 1995;94: Chi KH, Chan WK, Shu CH, Lo SS, Chen SY, Yen SH, et al. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil and leucovorin using a weekly 24-h infusion schedule for the treatment of patients with nasopharyngeal carcinoma. Cancer 1995;76: Liaw CC, Liaw SJ, Wang CH, Chiu MC, Huang JS. Transient hyperammonemia related to chemotherapy with continuous infusion of high-dose 5-fluorouracil. Anticancer Drugs 1998;9:311 5.
CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER
CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER Dr Elizabeth Smyth Royal Marsden, UK ESMO Gastric Cancer Preceptorship Valencia 2017 IMPORTANT CONSIDERATIONS WHEN TREATING ADVANCED GASTRIC CANCER Short OS Pain
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationIrinotecan. Class:Camptothecin. Indications : _Cervical cancer. _CNS tumor. _Esophageal cancer. _Ewing s sarcoma. _Gastric cancer
Irinotecan Class:Camptothecin Indications : _Cervical cancer _CNS tumor _Esophageal cancer _Ewing s sarcoma _Gastric cancer _Nonsmall cell lung cancer _Pancreatic cancer _Small cell lung cancer _Colorectal
More informationIrinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination
Clinical Report Chemotherapy 2002;48:94 99 Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination N.B. Tsavaris a A. Polyzos b K. Gennatas c
More informationLipoplatin monotherapy for oncologists
Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable
More informationBelotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer
J Lung Cancer 2010;9(1):15-19 Belotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer Purpose: Belotecan (Camtobell R ; Chong Keun Dang Co., Seoul,
More informationCombination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine
Gastric Cancer (2008) 11: 201 205 DOI 10.1007/s10120-008-0484-5 Original article 2008 by International and Japanese Gastric Cancer Associations Combination chemotherapy with cisplatin and irinotecan in
More informationVinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial
Original article Annals of Oncology 14: 699 703, 2003 DOI: 10.1093/annonc/mdg199 Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II
More informationONCOLOGY LETTERS 2: , 2011
ONCOLOGY LETTERS 2: 241-245, 2011 Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationWeekly 24-hour Infusional 5-Fluorouracil as Initial Treatment for Advanced Gastric Cancer with Acute Disseminated Intravascular Coagulation
Weekly 24-hour Infusional 5-Fluorouracil as Initial Treatment for Advanced Gastric Cancer with Acute Disseminated Intravascular Coagulation TA-CHEN HUANG 1,2,3, KUN-HUEI YEH 1,3,4, ANN-LII CHENG 1,3,5
More informationOncologist. The. Gastrointestinal Cancer. Phase II Study of 5-fluorouracil, Doxorubicin, and Mitomycin C for Metastatic Small Bowel Adenocarcinoma
The Oncologist Gastrointestinal Cancer Phase II Study of 5-fluorouracil, Doxorubicin, and Mitomycin C for Metastatic Small Bowel Adenocarcinoma MICHAEL K. GIBSON, a CHRISTINA A. HOLCROFT, b,c LARRY K.
More informationTwo Cases of Bile Duct Carcinoma which Showed Remarkable Response to a Combination of S-1 plus Cisplatinum (CDDP)
Two Cases of Bile Duct Carcinoma which Showed Remarkable Response to a Combination of S-1 plus Cisplatinum (CDDP) Kazuhiko Hayashi, MD Kazumi Uchida, MD Masakazu Yamamoto, MD Kenji Yoshitoshi, MD Ken Takasaki,
More informationOriginal article. Introduction
Gastric Cancer (2009) 12: 153 157 DOI 10.1007/s10120-009-0517-8 Original article 2009 by International and Japanese Gastric Cancer Associations Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU)
More informationMaterials and Methods
RESEARCH ARTICLE Comparative Analysis of the Efficacy and Safety of Oxaliplatin Plus 5-Fluorouracil/Leucovorin (Modified FOLFOX6) with Advanced Gastric Cancer Patients having a Good or Poor Performance
More informationEvaluation of efficacy and toxicity of systemic chemotherapy of combined epirubicin, cisplatin and bolus 5- fluorouracil for hepatobiliary tumors
Turkish Journal of Cancer Volume 36, No.2, 2006 69 Evaluation of efficacy and toxicity of systemic chemotherapy of combined epirubicin, cisplatin and bolus 5- fluorouracil for hepatobiliary tumors GÜZ
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed
More informationOverview. Author Summary: Abstract and Brief Discussion
Overview First Published Online October 1, 2014 DOI: 10.1634/theoncologist.2014-0223 Title: S-1 as Monotherapy or in Combination With Leucovorin as Second-Line Treatment in Gemcitabine-Refractory Advanced
More informationCLINICAL INVESTIGATION
Research Article CLINICAL INVESTIGATION Research on the treatment of metastatic colon cancer patients treated by FOLFOXIRI: Efficacy and toxicity of first-line treatment in stage IV metastatic colorectal
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationVision of the Future: Capecitabine
Vision of the Future: Capecitabine CHRIS TWELVES Cancer Research Campaign Department of Medical Oncology, University of Glasgow, and Beatson Oncology Centre, Glasgow, United Kingdom Key Words. Capecitabine
More informationKeywords gastric cancer; metastatic; chemotherapy; paclitaxel; continuous infusion. Correspondence to: C. Bokemeyer
doi: 10.1054/ bjoc.2000.1295, available online at http://www.idealibrary.com on A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients
More informationAntiemetic Prophylaxis with Ondansetron and Methylprednisolone vs Metoclopramide and Methylprednisolone in Mild and Moderately Emetogenic Chemotherapy
218 Journal of Pain and Symptom Management Vol. 18 No. 3 September 1999 Original Article Antiemetic Prophylaxis with Ondansetron and Methylprednisolone vs Metoclopramide and Methylprednisolone in Mild
More informationFOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients
Japanese Journal of Clinical Oncology, 2016, 46(1) 57 62 doi: 10.1093/jjco/hyv148 Advance Access Publication Date: 24 November 2015 Original Article Original Article FOLFOX-4 as second-line therapy after
More informationPhase II study of sequential high-dose methotrexate and fluorouracil. combined, with doxorubicin, as a neoadjuvant chemotherapy
Gastric Cancer (2001) 4: 192 197 Original article 2001 by International and Japanese Gastric Cancer Associations Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin
More informationThree-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study
Original article Annals of Oncology 13: 1080 1086, 2002 DOI: 10.1093/annonc/mdf186 Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study H. Soto Parra
More informationCombination of three cytotoxic agents in small-cell lung cancer
Cancer Chemother Pharmacol (2013) 71:413 418 DOI 10.1007/s00280-012-2022-8 ORIGINAL ARTICLE Combination of three cytotoxic agents in small-cell lung cancer G. P. Stathopoulos D. Trafalis J. Dimitroulis
More informationClinical Trials for Liver and Pancreatic Cancer in Taiwan
Japan - Taiwan Joint Symposium on Medical Oncology Session 6 Hepatobiliary and pancreatic cancers Clinical Trials for Liver and Pancreatic Cancer in Taiwan Li-Tzong Chen 1,2 *, Jacqueline Whang-Peng 1,3
More informationChemotherapy of Breast Cancer
Japan - Taiwan Joint Symposium on Medical Oncology Session 7 Breast cancer journal homepage:www.cos.org.tw/web/index.asp Chemotherapy of Breast Cancer Mei-Ching Liu Department of Medicine, Koo Foundation
More informationPILOT STUDY OF CONCURRENT CHEMO-RADIOTHERAPY FOR ADVANCED NASOPHARYNGEAL CARCINOMA (Forum for Nuclear Cooperation in Asia)
PILOT STUDY OF CONCURRENT CHEMO-RADIOTHERAPY FOR ADVANCED NASOPHARYNGEAL CARCINOMA (Forum for Nuclear Cooperation in Asia) Dr. Miriam Joy C. Calaguas Dept. of Radiation Oncology St. Luke s Medical Center
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationPing-Tsung Chen, MD; Chuang-Chi Liaw, MD
Original Article 167 Intravenous Ondansetron plus Intravenous Dexamethasone with Different Ondansetron Dosing Schedules during Multiple Cycles of Cisplatin-based Chemotherapy Ping-Tsung Chen, MD; Chuang-Chi
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationNeoadjuvant chemotherapy in advanced gastric cancer with noncurative factors: a Phase II study with 5-fluorouracil, leucovorin, and cisplatin
A. Gastric Nashimoto Cancer et (1999) al.: Neoadjuvant 2: 57 63 chemotherapy with FLP 57 1999 by International and Japanese Gastric Cancer Associations Original article Neoadjuvant chemotherapy in advanced
More informationAccepted 12 April 2006 Published online 13 November 2006 in Wiley InterScience ( DOI: /hed.
ORIGINAL ARTICLE PHASE II ANALYSIS OF PACLITAXEL AND CAPECITABINE IN THE TREATMENT OF RECURRENT OR DISSEMINATED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK REGION Jens D Bentzen, MD, 1 Hanne Sand Hansen,
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationOWa 22 80) :IEZ
Clinical Study Report: 20025409 Part 2 Date: 22 September 2008 OWa 22 80) 06 --- :IEZ Page 1 SYNOPSIS Name of the Sponsor: Name of Finished Product: Name of Active Ingredient: Immunex Corporation Panitumumab
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationSUPPLEMENTARY INFORMATION In format provided by Sebti et al. (NOVEMBER 2011)
Supplementary Information S4 Clinical trials with farnesyltransferase inhibitors Drug(s) Disease Phase Patients Median Age Tipifarnib CR Clinical response PR HI SD PD MD FT or Prenylation Response rate
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.6.2483 RESEARCH ARTICLE Gemcitabine Plus Nedaplatin as Salvage Therapy is a Favorable Option for Patients with Progressive Metastatic Urothelial Carcinoma After
More informationIntegrating Oxaliplatin into the Management of Colorectal Cancer
Integrating Oxaliplatin into the Management of Colorectal Cancer HANS-JOACHIM SCHMOLL, a JIM CASSIDY b a Martin-Luther-University Halle-Wittenberg, Halle, Germany; b University of Aberdeen, Aberdeen, UK
More informationGallbladder Cancer. GI Practice Guideline. Michael Sanatani, MD, FRCPC (Medical Oncologist) Barbara Fisher, MD, FRCPC (Radiation Oncologist)
Gallbladder Cancer GI Practice Guideline Michael Sanatani, MD, FRCPC (Medical Oncologist) Barbara Fisher, MD, FRCPC (Radiation Oncologist) Approval Date: September 2006 This guideline is a statement of
More informationRetrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal patients in the adjuvant setting
ORIGINAL ARTICLE CAPOX AND mfolfox6 DOSE INTENSITY AND CLINICAL OUTCOMES IN STAGE III CRC, Mamo et al. Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal
More informationYuh-Min Chen, MD, PhD; Reury-Perng Perng, MD, PhD; Jen-Fu Shih, MD; Chun-Ming Tsai, MD; and Jacqueline Whang-Peng, MD
Chemotherapy for Non-small Cell Lung Cancer in Elderly * Yuh-Min Chen, MD, PhD; Reury-Perng Perng, MD, PhD; Jen-Fu Shih, MD; Chun-Ming Tsai, MD; and Jacqueline Whang-Peng, MD Study objective: To determine
More informationKey words: advanced colorectal cancer, metastatic, irinotecan, 5-fluorouracil, leucovorin.
Original Article 297 Decreasing Dosage of Irinotecan, 5-Flurouracil (5-FU) and Leucovorin (LV) in the Treatment of Advanced and /or Metastatic Colorectal Cancer: A Phase II Study Jen-Seng Huang, MD; Cho-Li
More informationAHFS Final. IV and intraperitoneal regimen for. Criteria Used in. Strength. Strength. Use: Based on. taxane (either IV. following
AHFS Final Determination of Medical Acceptance: Off-label Use of Sequential IV Paclitaxel, Intraperitoneal Cisplatin, and Intraperitoneal Paclitaxel for Initial Adjuvan nt Treatment of Optimally Debulked
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationLow Dose Docetaxel Combined With Low Dose Capecitabine in Treatment of Metastatic Breast Cancer Previously Treated With Anthracycline
Low Dose Docetaxel Combined With Low Dose Capecitabine in Treatment of Metastatic Breast Cancer Previously Treated With Anthracycline Rabab Mahmoud and Omnia Abd-elfattah Clinical Oncology Department,
More informationSmall cell lung cancer (SCLC) comprises approximately
Original Article Efficacy and Toxicity of Belotecan for Relapsed or Refractory Small Cell Lung Cancer Patients Gun Min Kim, MD,* Young Sam Kim, MD, PhD, Young Ae Kang, MD, PhD, Jae-Heon Jeong, MD, Sun
More informationBCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum
BCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum Protocol Code: Tumour Group: Contact Physician: HNAVFUP Head and Neck
More informationPaclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Paclitaxel Gynaecological Cancer PROTOCOL REF: MPHAGYNPAC (Version No: 1.0) Approved for use in: Second/ third line option for advanced ovarian cancers (3 weekly
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationGemcitabine and Carboplatin in Patients with Refractory or Progressive Metastatic Breast Cancer after Treatment
DOI: 10.18056/seci2014.6 Gemcitabine and Carboplatin in Patients with Refractory or Progressive Metastatic Breast Cancer after Treatment Zedan A 1, Soliman M 2, Sedik MF 1 1 Medical Oncology Department,
More informationPlattenepithelkarzinom des Ösophagus, 1 st -line
Plattenepithelkarzinom des Ösophagus, 1 st -line AIO-STO-0309 An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationNovel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial 2014-309-00CH1 Presenter: Jifang Gong, Beijing Cancer Hospital Lin Shen 1, Li Zhang 2, Hongyun Zhao 2, Wenfeng Fang 2,
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationPhase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer
Original article Annals of Oncology 13: 1862 1867, 2002 DOI: 10.1093/annonc/mdf308 Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer V.
More informationThe detection rate of early gastric cancer has been increasing owing to advances in
Focused Issue of This Month Sung Hoon Noh, MD, ph.d Department of Surgery, Yonsei University College of Medicine E - mail : sunghoonn@yuhs.ac J Korean Med Assoc 2010; 53(4): 306-310 Abstract The detection
More informationPhase II study of Gemcitabine and Cisplatin Regimen in Advanced Non-Small Cell Lung Cancer (NSCLC).
Phase II study of Gemcitabine and Cisplatin Regimen in Advanced Non-Small Cell Lung Cancer (NSCLC). Hoseinzadeh Mollayosefy M., 1,* Iravani M., 1 Ghavamzadeh A., 1 Toogheh Gh., 2 Alimoghaddam K. 1 1 Department
More informationPatient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationA Comparison of Gemcitabine in Two Doses for Stage III or IV Non-small Cell Lung Cancer: a Multi-Institutional Phase II Study
J Lung Cancer 2007;6(1):1-7 A Comparison of Gemcitabine in Two Doses for Stage III or IV Non-small Cell Lung Cancer: a Multi-Institutional Phase II Study Purpose: Since the combination of cisplatin plus
More informationFluorouracil/Leucovorin/Interferon α-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration.
Chapter 8 Fluorouracil/Leucovorin/Interferon α-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. Jan Buter, Harm A.M. Sinnige, Dirk Th. Sleijfer, Elisabeth
More informationBCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy
BCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GIRCRT Gastrointestinal
More informationSupplementary Material
1 Supplementary Material 3 Tumour Biol. 4 5 6 VCP Gene Variation Predicts Outcome of Advanced Non-Small-Cell Lung Cancer Platinum-Based Chemotherapy 7 8 9 10 Running head: VCP variation predicts NSCLC
More informationClinical Medicine Insights: Oncology
Clinical Medicine Insights: Oncology O r i g i n a l R e s e a r c h Open Access Full open access to this and thousands of other papers at http://www.la-press.com. A Phase II Study of S-1 Monotherapy as
More informationManagement of Advanced Colorectal Cancer in Older Patients
Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate
More informationCisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,
More informationSingle Agent Irinotecan for The Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN)
ORIGINAL RESEARCH Single Agent Irinotecan for The Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN) 1 Gilbert J, 1 Dang T, 2 Cmelak A, 3 Shyr Y, 4 Netterville J, 4 Burkey
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 18 JUNE 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Weekly Infusional High-Dose Fluorouracil (), Plus Folinic Acid (/FA), or /FA Plus Biweekly Cisplatin in Advanced
More informationStudy population The study population comprised patients with the following characteristics:
Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell
More informationAccepted 24 October 2007 Published online 22 January 2008 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.
ORIGINAL ARTICLE PHASE II STUDY OF GEFITINIB FOR THE TREATMENT OF RECURRENT AND METASTATIC NASOPHARYNGEAL CARCINOMA Daniel T. T. Chua, MD, 1 William I. Wei, MD, 2 Maria P. Wong, MD, 3 Jonathan S. T. Sham,
More informationOriginal article. Introduction
Original article Annals of Oncology 15: 1204 1209, 2004 DOI: 10.1093/annonc/mdh312 Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic
More informationEASTERN COOPERATIVE ONCOLOGY GROUP
EASTERN COOPERATIVE ONCOLOGY GROUP E5204 INTERGROUP RANDOMIZED PHASE III STUDY OF POSTOPERATIVE OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN VS OXALIPLATIN, 5-FLUOROURACIL, LEUCOV- ORIN AND BEVACIZUMAB FOR
More informationOriginal article. Introduction
Original article Annals of Oncology 13: 1192 1196, 2002 DOI: 10.1093/annonc/mdf201 Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin
More informationUse of Taxanes in Older Breast Cancer Patients
SIOG Guidelines Update 2014: Use of Taxanes in Older Breast Cancer Patients Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Fundamental steps Task Force (TF) on
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationClinicopathological Characteristics and Outcome Indicators of Stage II Gastric Cancer According to the Japanese Classification of Gastric Cancer
Clinicopathological Characteristics and Outcome Indicators of Stage II Gastric Cancer According to the Japanese Classification of Gastric Cancer HITOSHI OJIMA 1, KEN-ICHIRO ARAKI 1, TOSHIHIDE KATO 1, KAORI
More informationBCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy
BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GICART Gastrointestinal
More informationSetting The setting was secondary care. The economic study was carried out in the UK.
Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer Robinson P, von der Masse H, Bhalla S, Kielhorn A, Aristides M, Brown A, Tilden D
More informationRisk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer
Gastric Cancer (2013) 16:133 139 DOI 10.1007/s10120-012-0158-1 ORIGINAL ARTICLE Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer Toru Aoyama Takaki Yoshikawa Tsutomu
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationOriginal article. E. Mitry 1 *, J.-Y. Douillard 2, E. Van Cutsem 3, D. Cunningham 4, E. Magherini 5, D. Mery-Mignard 5, L. Awad 5 & P.
Original article Annals of Oncology 15: 1013 1017, 2004 DOI: 10.1093/annonc/mdh267 Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients
More informationAdjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationPaclitaxel in Breast Cancer
Paclitaxel in Breast Cancer EDITH A. PEREZ Mayo Foundation and Mayo Clinic Jacksonville, Jacksonville, Florida, USA Key Words. Paclitaxel Antineoplastic agents Breast neoplasms Clinical trials ABSTRACT
More informationBone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When PET Scans Findings Are Equivocal: A Case Report
Bone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When Scans Findings Are Equivocal: A Case Report Yuk-Wah Tsang 1, Jyh-Gang Leu 2, Yen-Kung Chen 3, Kwan-Hwa Chi 1,4
More informationFirst-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status
562 First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status JUN-EUL HWANG 1, HA-NA KIM 1, DAE-EUN KIM 1, HYUN-JEONG SHIM 1, WOO-KYUN BAE
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationNCCP Chemotherapy Regimen
Modified Roswell Park (Fluorouracil 500mg/m 2 and Folinic Acid 50mg weekly x 6) Regimen INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Treatment of metastatic colorectal cancer C18 00427a Adjuvant
More informationGourgou-Bourgade, et al DOI: /JCO
Impact of FOLFIRINO compared with gemcitabine on Quality-of-Life in Patients with Metastatic Pancreatic Cancer: results from the PRODIGE 4/ACCORD 11 randomized trial Gourgou-Bourgade, et al DOI: 10.1200/JCO.2012.44.4869
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More information